Supernus Pharmaceuticals, Inc. has announced a significant transition following its merger with Indivior Pharmaceuticals, Inc. The company filed a post-effective amendment to deregister its securities on November 2, 2026, as part of the merger agreement that took effect on the same day.

This merger is a pivotal moment for Supernus, as it will cease to be a public reporting company. The merger will have implications for the pharmaceutical industry, particularly in the realm of mergers and acquisitions, as companies navigate the evolving landscape.

Background

Supernus Pharmaceuticals, Inc. is a Delaware-based company classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol SUPN. Recently, Supernus has been active in filing various forms, including multiple S-8 registrations and 8-K reports, with the latest filings on November 2, 2026.

What the Filing Says

The filing indicates that Supernus has deregistered all securities registered under previous S-8 registration statements that remain unissued and unsold. This includes shares related to the company’s 2012 Equity Incentive Plan and 2021 Equity Incentive Plan. The filing states, "The Company has determined to deregister all of the securities registered under the Registration Statements that remain unsold as of the Effective Time." This decision follows the completion of the merger with Indivior.

Impact

The deregistration of securities will affect shareholders and potential investors in Supernus Pharmaceuticals, as the company transitions to a wholly owned subsidiary of Indivior. The move may also influence the competitive dynamics within the pharmaceutical preparations sector, as companies adapt to the changes brought about by this merger.

What's Next

The filing does not specify what happens next for Supernus Pharmaceuticals following the deregistration. However, the company will continue to operate as a subsidiary of Indivior, which may lead to further developments in its business strategy and operations.